[1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum

C45H38N6OPt — CID 176844741

IUPAC[1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum
SMILESCn1ccn(-c2cccc(Oc3ccc4c5c6c(c7ccccc7n6C)c6c(c7ccccc7n6C)c5n(-c5cc(C(C)(C)C)ccn5)c4c3)c2)c1=[Pt]
InChIInChI=1S/C45H38N6O.Pt/c1-45(2,3)28-20-21-46-38(24-28)51-37-26-31(52-30-13-11-12-29(25-30)50-23-22-47(4)27-50)18-19-34(37)41-43-39(32-14-7-9-16-35(32)48(43)5)42-40(44(41)51)33-15-8-10-17-36(33)49(42)6;/h7-26H,1-6H3;
InChIKeyZRAVMNUHOPJSOB-UHFFFAOYSA-N
MW873.92 g/mol
LogP10.77
Rot. Bonds4

About [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum

[1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum (PubChem CID 176844741) has the molecular formula C45H38N6OPt and a molecular weight of 873.92 g/mol. Its IUPAC name is [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum.

Molecular Properties

Compound Name[1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum
PubChem CID176844741
Molecular FormulaC45H38N6OPt
Molecular Weight873.92 g/mol
Exact Mass873.28
IUPAC Name[1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum
SMILESCn1ccn(-c2cccc(Oc3ccc4c5c6c(c7ccccc7n6C)c6c(c7ccccc7n6C)c5n(-c5cc(C(C)(C)C)ccn5)c4c3)c2)c1=[Pt]
InChIInChI=1S/C45H38N6O.Pt/c1-45(2,3)28-20-21-46-38(24-28)51-37-26-31(52-30-13-11-12-29(25-30)50-23-22-47(4)27-50)18-19-34(37)41-43-39(32-14-7-9-16-35(32)48(43)5)42-40(44(41)51)33-15-8-10-17-36(33)49(42)6;/h7-26H,1-6H3;
InChIKeyZRAVMNUHOPJSOB-UHFFFAOYSA-N
XLogP10.77
TPSA46.77 Ų
H-Bond Donors
H-Bond Acceptors7
Rotatable Bonds4
Heavy Atoms53
Complexity

Lipinski Rule of Five

2 violations

RuleValue
MW ≤ 500873.92
LogP ≤ 510.77
H-Bond Donors ≤ 50
H-Bond Acceptors ≤ 107

Analyze [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Related Compounds

Frequently Asked Questions

What is the IUPAC name of [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum?
The IUPAC name of [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum (CID 176844741) is [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum.
What is the SMILES notation for [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum?
The canonical SMILES for [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum is Cn1ccn(-c2cccc(Oc3ccc4c5c6c(c7ccccc7n6C)c6c(c7ccccc7n6C)c5n(-c5cc(C(C)(C)C)ccn5)c4c3)c2)c1=[Pt].
What is the InChIKey of [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum?
The InChIKey is ZRAVMNUHOPJSOB-UHFFFAOYSA-N. The full InChI is InChI=1S/C45H38N6O.Pt/c1-45(2,3)28-20-21-46-38(24-28)51-37-26-31(52-30-13-11-12-29(25-30)50-23-22-47(4)27-50)18-19-34(37)41-43-39(32-14-7-9-16-35(32)48(43)5)42-40(44(41)51)33-15-8-10-17-36(33)49(42)6;/h7-26H,1-6H3;.
What are the key properties of [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum?
[1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum has a molecular weight of 873.92 g/mol, XLogP of 10.77, 4 rotatable bonds, 0 hydrogen bond donors, and 7 hydrogen bond acceptors.
Where does this data come from?
All data for [1-[3-[[9-(4-tert-butyl-2-pyridinyl)-18,27-dimethyl-9,18,27-triazaheptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26]heptacosa-1,3(8),4,6,10,12,14,16,19,21,23,25-dodecaen-6-yl]oxy]phenyl]-3-methylimidazol-2-ylidene]platinum is sourced from PubChem (CID 176844741), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).